Reference Materials
Enhancing Sensitivity of cfDNA Copy Number by Increasing Plasma Sample Volume
Organization: nRichDX
Venue: International Society of Liquid Biopsy (ISLB) 6th Annual Congress
Date: November 2024
This poster describes and characterizes increased cfDNA yield from extractions of larger input sample volumes of plasma and increased assay sensitivity using the nRichDX Revolution cfDNA Max 20 Kit. Extracting cfDNA from small-volume plasma samples poses challenges in achieving sufficient actionable cfDNA. Increasing the initial sample volume significantly enhances the capture of total and actionable cfDNA.
The Mutational Landscape of Circulating Tumor Cells in Pancreatic Cancer
Organization: Dartmouth Hitchcock Medical Center
Venue: Association for Molecular Pathology (AMP) 2024 Annual Meeting
Date: November 2024
This poster describes isolation of CTCs from pancreatic cancer patients post surgery and adjuvant therapy using the nRichDX Revolution Sample Prep System and two nRichDX kits: the Revolution CTC Isolation Kit (Epithelial Origin) and the Revolution cfDNA Max 20 Kit followed by NGS library prep and Whole Exome Sequencing (WES) analysis.
Clinical Validation of Cell-free DNA (cfDNA) Extraction from Whole Blood Plasma using the nRichDX® Revolution Max 20 Kit and Sample Prep System
Organization: Dartmouth Hitchcock Medical Center
Venue: Association for Molecular Pathology (AMP) 2024 Annual Meeting
Date: November 2024
This poster describes clinical validation of the nRichDX Revolution Sample Prep System and extraction of cfDNA from blood plasma using the nRichDX Revolution Max 20 Kit. cfDNA was quality control analyzed and cfDNA stability determined on the Agilent TapeStation, followed by stability testing of isolated cfDNA and analysis by Next Generation Sequencing (NGS).
Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine
Organizations: nRichDX and Agilent
Venue: Association for Molecular Pathology (AMP) 30th Annual Meeting and Expo
Date: November 2024
This poster describes the extraction of 12, 50 mL urine samples spiked with free RNA extracted from LnCAP cells containing the PTEN mutation. Parallel extractions were performed using the Revolution cfTNA Max 50 Kit and the Zymo ZR Urine RNA Isolation Kit and the Norgen Urine Cell-free Circulating and Viral Nucleic Acid Purification Maxi Kit for purposes of comparison.
Enhanced cell-free RNA (cfRNA) recovery for liquid biopsy applications: Comparative analysis using controlled RNA samples for early and advanced cancer detection
Organization: nRichDX
Venue: AACR Special Conference on Liquid Biopsy
Date: November 2024
This poster describes extraction of cfRNA from plasma using the nRichDX Revolution cfTNA Kit as compared to Qiagen's QIAamp extraction on the QIAvac vacuum manifold method. Workflow and performance characteristics of each method are compared.
Integrated Liquid Biopsy for Prostate Cancer: Capturing Circulating Tumor Cells and Urinary Cell-Free Total Nucleic Acid
Organizations: Anchor Molecular and nRichDX
Venue: Cancer Genomics Consortium (CGC) 2024 15th Annual Meeting
Date: August 2024
This poster describes the extraction of LNCaP prostate cancer cells from whole blood and the TMPRSS2-ERG prostate cancer RNA fusion as circulating cell-free nucleic acid from urine using nRichDX's Revolution CTC Enrichment (Epithelial) Kit and the Revolution cfTNA Max 20 Kit.Current Perspectives on Pre-Analytical Variables that Impact Liquid Biopsy Test Sensitivity (video)
Organization: nRichDX
Venue: Webinar
Date: July 2024
This webinar features keynote presenter Tina Lockwood, PhD.; Division Head, Genetics and Solid Tumors at the University of Washington School of Medicine and concludes with a Q&A session with the webinar attendees at the live event.
Please note that the slides are left justified in the adjacent video frame due to the 3-person Q&A panel at the end. Select the square full-screen icon in the lower right corner of the video for best viewing quality.
Unraveling the Link Between Total cfDNA Quantified by Agilent TapeStation Cell-free DNA ScreenTape and Actionable cfDNA Molecules Measured on Downstream Assays
Organizations: Agilent and nRichDX
Venue: Association for Molecular Pathology (AMP) Europe Congress 2024
Date: June 2024
This poster aims to show the correlation between total cfDNA quantified by Agilent Cell-free DNA ScreenTape assay and the detection of actionable cfDNA molecules throughqPCR. nRichDX Revolution Sample Prep demonstrated high extraction efficiency of cfDNA at 89% across 38 samples. Notably, cfDNA peaks are clearly observed for cfDNA monomers, dimers, and trimers. cfDNA dimers and especially trimers, typically being the rarest forms of cfDNA, are often undetectable using other methods.
Exploring Liquid Biopsy for the Detection of Bladder Cancer: Unraveling RNA Fusions
Organizations: Anchor Molecular and nRichDX
Venue: AACR Special Conference in Cancer Research: Bladder Cancer: Transforming the Field
Date: May 2024
This poster describes research using whole urine samples in a liquid biopsy context for the detection of the RNA fusions specifically associated with bladder cancer: ETV6-NTRK3 and PRCC-TFE3. Using the nRichDX Revolution cfTNA (total nucleic acid) Kit and a spike-in standard from Anchor Molecular, the poster discusses high yield extraction of circulating-free nucleic acid for the detection of cancer-associated RNA fusions.VIDEO: Q&A of Poster Titled, "Exploring Liquid Biopsy for the Detection of Bladder Cancer: Unraveling RNA Fusions"
Organizations: Anchor Molecular and nRichDX
Venue: Online posting
Date: June 2024
In this brief video Q&A, Dr. Nafiseh Jafari, CSO of nRichDX, discusses the objectives of this study, its methods, and next steps.
Enhanced DNA Extraction from Large Whole Urine Volumes: Implications for Prostate Cancer Detection
Organization: nRichDX
Venue: New Frontiers in Liquid Biopsies: Data, Technology and Translational Potential (NIH)
Date: May 2024
This poster describes extraction of cfDNA from urine using the nRichDX Revolution cfDNA Max 20 Kit as compared to the Zymo® Quick-DNA Kit. Results demonstrate higher yield of actionable DNA molecules evidenced by lower Ct value using the PTEN mutation - a tumor suppressor gene frequently altered in prostate cancers - as an example marker. Workflow between the two kits is also compared.
Enhancing urine-based cfDNA detection for prostate cancer diagnosis through increased input volume
Organizations: Agilent and nRichDX
Venue: American Association for Cancer Research 2024 Annual Meeting
Date: April 2024
This poster, jointly presented with Agilent, describes sensitive cfDNA detection using the enhanced nRicher Cartridge input urine volume in a single extraction. TapeStation tracings demonstrated proportionally increasing cfDNA yield with increasing sample volume when using the nRichDX Revolution system. qPCR confirmed the detection of the PIK3CA prostate cancer mutation in all cfDNA eluates extracted using the nRichDX Revolution system. The mutation was not detected in any eluates extracted with the MagMax cfDNA Isolation kit.
First-void urine as a non-invasive proxy for plasma in prostate cancer-related liquid biopsy applications.
Organizations: Novosanis and nRichDX
Venue: American Association for Cancer Research 2024 Annual Meeting
Date: April 2024
This poster, jointly presented with Novosanis, describes a comparison of first-void urine samples with plasma samples. Further investigations are needed to evaluate clinical samples and biomarkers to establish a robustcorrelation between cfDNA levels and cancer types and stages. This study highlights the potential of first-void urine samples as a reliable proxy for blood-based liquid biopsy applications.
Achieving sensitivity of 0.1% variant allele frequency (VAF) in plasma and urine with the nRichDX revolution sample prep system evaluated on the MassARRAY® system
Organizations: Agena Bioscience and nRichDX
Venue: American Association for Cancer Research 2024 Annual Meeting
Date: April 2024
This poster, jointly presented with Agena Bioscience, describes sensitive variant allele frequency detection of 0.1% on the Agena MassARRAY platform when coupled with high-yield analyte extraction from both plasma and urine samples using Revolution Sample Prep.
Assessment of Cell-free DNA (cfDNA) Extraction Using the nRichDX Revolution Sample Prep System from Plasma, Urine, and Pancreatic Cyst Fluid
Organization: Dartmouth Hitchcock Medical Center
Venue: Association for Molecular Pathology (AMP) 2023 Annual Meeting
Date: November 2023
This poster from the Tsongalis Lab at Dartmouth Hitchcock describes cfDNA extraction and analysis using the nRichDX Revolution System from three different human clinical sample types used in liquid biopsy: blood plasma, urine, and pancreatic cyst fluid.
Unraveling the Link Between Total cfDNA Quantified by Agilent TapeStation Cell-free DNA ScreenTape and Actionable cfDNA Molecules Measured on Downstream Assays
Organizations: Agilent and nRichDX
Venue: Association for Molecular Pathology (AMP) 2023 Annual Meeting
Date: November 2023
This poster, jointly presented with Agilent Technologies, describes high-quality cfDNA extraction using the nRichDX Revolution Sample Prep System followed by analysis using the Agilent TapeStation ScreenTape. Actionable cfDNA molecules as compared to artifacts are described.Back-to-Back Presentations (video):
- nRichDX Revolution Sample Prep System for Liquid Biopsy - Overview and Performance Data (Jafari)
- Improving the Efficiency of Liquid Biopsy Extraction Using the nRichDX Revolution System (Sathyanarayana)
Organizations: Dartmouth Hitchcock Medical Center, nRichDX
Venue: Association for Molecular Pathology (AMP) 2023 Annual Meeting - Innovation Spotlight Stage 2
Date: November 2023
In this video, Nafiseh Jafari, PhD, CSO of nRichDX presents an overview of the Revolution Sample Prep System for liquid biopsy and Shiva Sathyanarayana, PhD from the Tsongalis Lab at Dartmouth Hitchcock Medical Center, provide an overview of Liquid Biopsy and the Revolution Sample Prep System from nRichDx. Experimental outline and performance data are shared.
Pre-analytical Considerations for Minimum Residual Disease Detection by Next-Generation Sequencing (video)
Organizations: Agilent, nRichDX, Strata Oncology
Venue: Webinar
Date: October 2023
In this webinar, Scott Tomlins, MD, PhD and Travis Reeder from Strata Oncology, will highlight the importance of cfDNA yield and purity using the Revolution Sample Prep System from nRichDx for cfDNA extraction as well as reliable pre-analytical quality control with the Agilent Cell-free DNA ScreenTape assay and the TapeStation systems, and their relation to NGS-based MRD testing. Nafiseh Jafari, PhD, CSO of nRichDX also provides an introduction to the Revolution System and performance data.
Extraction of Multiple Analytes in Liquid Biopsy May Improve the Diagnosis of Breast Cancer
Organization: nRichDX
Venue: Cancer Genomics Consortium (CGC) 2023 14th Annual Meeting
Date: August 2023
This poster describes the extraction of analytes from two fractions from a single whole blood sample - cfDNA from the plasma fraction, and CTCs enrichment from the sample's buffy coat fraction - using the Revolution cfTNA Max 20 Kit and nRichDX's new Revolution CTC Enrichment (Epithelial) Kit.Current Perspectives on Liquid Biopsy Technologies (video)
Organization: UKE, nRichDX
Venue: Webinar
Date: April 2023
This webinar features keynote presenter Klaus Pantel, MD, PhD. Chairman of the Institute of Tumour Biology, University Medical Center Hamburg-Eppendorf, and Founder and Chairman of the European Liquid Biopsy Society (ELBS).
The nRichDX Revolution Sample Prep System™ enables recovery of more amplifiable copies and more cancer fraction detection from cfDNA as evaluated on the MassARRAY® System
Organization: Agena Bioscience, nRichDX
Venue: American Association for Cancer Research (AACR) Annual Meeting 2023
Date: April 2023
This poster demonstrates the Revolution System's ability to extract more amplifiable copies of cfDNA and ctDNA biomarkers from plasma samples of 5 mL and 20 mL as compared to a leading competitor's kit. Samples were spiked with cfDNA reference standard containing KRAS p.G12V mutation to a final concentration of 20ng/mL and run on the Agena Bioscience MassARRAY System.
Method Comparison of Commercially Available cfDNA Extraction Products for Minimum Residual Disease Next Generation Sequencing
Organization: Strata Oncology
Venue: Molecular & Precision Medicine (TRI-CON) 2023 Annual Meeting
Date: March 2023
This poster is a side-by-side comparison of the Revolution System's cfDNA Kit with several other methods. cfDNA was extracted and quality metrics and cfDNA yields were compared. Results indicate the Revolution Kit provided higher cfDNA yields and lower gDNA contamination as compared to other methods.
Detection of Somatic Variants in Breast Cancer from Large Volumes of Plasma Using the nRichDX Revolution System
Organization: nRichDX
Venue: Molecular & Precision Medicine (TRI-CON) 2023 Annual Meeting
Date: March 2023
This poster demonstrates the Revolution cfDNA isolation kit's ability to extract circulating cell-free deoxyribonucleic acid (cfDNA) from plasma samples of up to 20 mL in a single extraction. cfDNA total yield was measured via Qubit and characterized by TapeStation, and Ct values for a well-characterized breast cancer mutation were determined.
Higher Total RNA Yields and Sequenceable RNA is Attainable Using the nRichDX Revolution Sample Prep System Total Nucleic Acid Isolation Kit
Organization: nRichDX
Venue: Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo
Date: November 2022
This poster demonstrates the Revolution cell-free Total Nucleic Acid Isolation Kit's ability to extract circulating cell-free total nucleic acid (cfNA) including circulating free RNA (cfRNA) from plasma samples of up to 20 mL in a single extraction. High-performance Next Generation Sequencing (NGS) results from cfRNA were obtained as compared to two competing methods.
Colli-Pee® UAS™ Combined withnRichDX Revolution System™, a Promising Urinary Cell-free DNA Collection, Preservation and Extraction Workflow
Organization: University of Antwerp, nRichDX, Novosanis, DNA Genotek
Venue: Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo
Date: November 2022
This poster demonstrates the compatibility of the Colli-Pee and UAS urine collection system from Novosanis with the nRichDX Revolution Sample Prep System for extraction of cfDNA from up to 20 mL of urine in a single extraction. cfDNA yield, purity, and other factors were compared with other sample prep methods.Current Perspectives - Molecular Profiling of Urine for Prostate Cancer Diagnosis: Opportunities and Challenges (video)
Organization: University of Michigan, nRichDX, Novosanis
Venue: Webinar
Date: September 2022
This joint webinar with nRichDX partner Novosanis covers current opportunities and challenges of urine as a sample type for molecular profiling of prostate cancer from Keynote Presenter, Dr. Simpa Salami, Assistant Professor of Urology and Co-Director of the University of Michigan's Liquid Biopsy Core Laboratory.The Revolution Sample Prep System for Liquid Biopsy Applications (video)
Organization: nRichDX
Venue: Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting
Date: August 2022
This video provides a brief introduction to the Revolution Sample Prep System from Nafiseh Jafari, PhD of nRichDX.
Higher cfRNA Recovery and Precision from Large Urine Sample Volumes Using the nRichDX Revolution Sample Prep System
Organization: nRichDX
Venue: Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting
Date: August 2022
This poster demonstrates the Revolution Sample Prep System's ability to extract circulating free total nucleic acid (cfNA) and circulating free RNA (cfRNA) from urine samples of up to 20 mL in a single extraction.
Higher cfDNA Recovery and Precision from Large Urine Sample Volumes Using the nRichDX Revolution Sample Prep System
Organization: nRichDX
Venue: Cancer Genomics Consortium (CGC) 2022 13th Annual Meeting
Date: August 2022
This poster demonstrates the Revolution Sample Prep System's compatibility with the Novosanis® Colli-Pee® sample collection and stabilization system for recovery of cfDNA from urine samples of up to 20 mL in a single extraction.
MinION Nanopore Sequencing of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) extracted from human plasma using nRichDX Revolution System
Organization: nRichDX
Venue: Association for Molecular Pathology (AMP) 2021 Annual Meeting
Date: November 2021
This poster demonstrates the Revolution Sample Prep System's compatibility with Oxford Nanopore Technologies' MinION sequencing device for NGS sequencing of cfDNA and cfRNA.
Semi-Automated High Yield cfDNA Extraction Using nRichDX Revolution Sample Prep System on Eppendorf epMotion for Liquid Biopsy Development
Organization: nRichDX
Venue: Association for Molecular Pathology (AMP) 2021 Annual Meeting
Date: November 2021
This poster describes the Semi-Automated Workflow of Revolution Sample Prep on the Eppendorf epMotion 5073 liquid handler.
nRichDX Revolution Instrument and cfDNA isolation Kit for Extraction of cfDNA from Large Plasma and Urine Sample Volumes Improves Yield of Rare Targets
Organization: nRichDX
Venue: Association for Molecular Pathology (AMP) 2019 Annual Meeting
Date: November 2019
This poster introduces the Revolution Sample Prep System for extraction of cfDNA from plasma and urine samples as compared to a competing sample prep kit.
Assessment of the nRichDX Revolution Instrument and Isolation Kit for cell-free DNA Extraction from Liquid Biopsy
Organization: Dartmouth Hitchcock
Venue: Association for Molecular Pathology (AMP) 2019 Annual Meeting
Date: November 2019
This poster from the laboratory of Dr. Gregory Tsongalis evaluates the nRichDX Revolution Sample Prep System for extraction of cfDNA.